Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

6 août 2018

10:00
FARMINGTON, Conn., Aug. 6, 2018 /PRNewswire-PRWeb/ -- Diameter Health, a leading enabler of clinical insight through the cleansing, deduplication and enrichment of clinical data across the care continuum, today announced that its Chief Data...

09:30
Today, JNCCN?Journal of the National Comprehensive Cancer Network introduced new associate editors, who reflect the journal's growing focus on original research designed to improve the quality of cancer care delivery, worldwide. The expanding focus...

08:34
Olivia Orano has just delivered baby Myles, a beautiful 7lb baby boy!  Like any first time mothers, during the pregnancy, Olivia spent a lot of time developing a "birth plan," or a list of her preferences at time of delivery.  That list originally...

08:30
Immix Biopharma, Inc. announced today that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110. The dog showed a complete resolution of all...

08:30
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended June 30, 2018, and provided an overview of recent accomplishments and plans for its research...

08:00
Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been...

08:00
Eiger BioPharmaceuticals, Inc. , focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study conducted within the National Institutes of Health (NIH) at...

08:00
OncoSec Medical Incorporated (OncoSec) , a company developing intratumoral cancer immunotherapies, today announced that it has entered into a research collaboration agreement with the University of California, Los Angeles (UCLA) on behalf of Roger S....

08:00
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the...

07:30
Neovasc Inc. ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter...

07:01
Protagonist Therapeutics, Inc. today announced results from an independent blinded re-analysis of the Phase 2 PROPEL study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment of patients with ulcerative colitis (UC). No safety...

07:00
Glenmark Pharmaceuticals S.A. and Harbour BioMed announced today that they have entered into an exclusive license agreement for the Greater China territory to develop, manufacture and commercialize GBR 1302, Glenmark's bispecific antibody targeting...

07:00
DURHAM, N.C., Aug. 6, 2018 /PRNewswire-PRWeb/ -- In a new study published by STEM CELLS, researchers at Newcastle University, UK, describe a new organoid model that encompasses all human retinal cell types and that is responsive to light. Their work...

05:30
GB Sciences, Inc. has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory...

03:00
Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE    This analysis provides...

03:00
Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been...

03:00
A modern genetic test for a cancer patient contains more information than ever before: Too much, in fact, for modern digital medical records. That's a problem. A big, big data problem. But it's a problem with a solution...

02:00
Menarini Ricerche, une société du groupe Menarini, a annoncé aujourd'hui que le parrainage de l'étude de phase I/II en cours qui étudie le MEN1703/SEL24 pour le traitement des patients atteints de LMA récidivante / réfractaire (R/R) aux États-Unis a...


5 août 2018

06:02
Britannia Pharmaceuticals Ltd a annoncé la publication des résultats de la phase en double-aveugle de l'étude TOLEDO dans la revue Lancet Neurology[1]. Le traitement à base d'APO-go®/MOVAPO® (apomorphine) administré par perfusion sous-cutanée...


3 août 2018

11:23
Immunovia AB today announced that the Karolinska Institutet is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ?s...

06:39
Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1]. Treatment with APO-go®/MOVAPO® (apomorphine) subcutaneous infusion for 12 weeks gave significantly greater...


2 août 2018

16:05
Ionis Pharmaceuticals, Inc. , the leader in antisense therapeutics, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to IONIS-HTTRx (also known as RG6042) for the treatment of people with...

15:40
SEATTLE, Aug. 2, 2018 /PRNewswire-PRWeb/ -- The EndBrainCancer Initiative (EBCI, formerly the Chris Elliott Fund) received CITI certification to recruit caregivers to participate in brain cancer caregiver and patient clinical trials at the Pacific...

13:45
Dear Fellow Shareholders, I am pleased to announce that we have entered the second half of 2018 with strong momentum. Now that we have officially moved into our new state-of-the-art Cancer Screening Laboratory located in Rehovot, Israel we are...

13:18
AACC welcomed thousands of medical professionals and healthcare leaders at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo from July 29?August 2. The meeting showcased advancements in clinical testing technology and research that improve...

08:30
MiMedx Group, Inc. , a leading developer and marketer of regenerative and therapeutic biologics, today announced that the positive pain and foot function results from its Phase 2B clinical trial of micronized dHACM (dehydrated Human Amnion/Chorion...

08:06
Natera, Inc. , a leader in non-invasive genetic testing, today announced the publication of a study demonstrating the value of the company's Spectrum® preimplantation genetic screening for aneuploidy (PGT-A) to improve in vitro fertilization (IVF)...

08:00
CTI BioPharma Corp. today reported financial results for the second quarter and six months ended June 30, 2018. In July 2018, CTI BioPharma announced the continuation without modification of the PAC203 Phase 2 study following a planned interim...

08:00
GLATECTTM (glatiramer acetate injection, 20 mg/1 mL) is now the only glatiramer-based treatment covered by five provincial drug plans for patients new to glatiramer acetate for the treatment of relapsing-remitting multiple sclerosis (RRMS)...

08:00
GLATECTMC (acétate de glatiramère injectable, 20 mg/1 mL) est dorénavant le seul traitement à base de glatiramère couvert par les régimes d'assurance-médicaments de cinq provinces à l'intention des « patients n'ayant jamais reçu » d'acétate de...

08:00
Regenera Pharma, a biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced the enrollment of the first patient in a United States (US) Phase 3 study of RPh201 in NAION (nonarteritic anterior ischemic optic...

07:30
Avelas Biosciences, Inc., a clinical stage oncology-focused company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that the first patient has been dosed in Period 2 of...

07:30
Aevi Genomic Medicine, Inc. (the "Company") announced today financial and operational results for the three months ended June 30, 2018 and provided an overview of the Company's recent corporate progress. Second Quarter Financial Results and Recent...

07:10
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today that Clinical Cancer Research published results from a large cross validation study of DCISionRT® in patients...

07:00
ArmaGen, Inc., a privately held biotechnology company focused on developing groundbreaking therapies to treat severe neurological disorders, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development...

06:45
Mallinckrodt plc , a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 2 study assessing the efficacy and safety of investigational drug MNK-1411 (cosyntropin, also known as...

06:36
Medivir AB today announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). This clinical study will be conducted...


1 août 2018

19:27
CalciMedica announced that the first patients in a Phase 2a clinical study for acute pancreatitis have been dosed with its proprietary calcium release-activated calcium (CRAC) channel inhibitor CM4620. The study is intended to provide safety and...

16:45
Mallinckrodt plc , a leading global specialty pharmaceutical company, today announced it has initiated a company-sponsored, experimental, proof-of-concept study of nitric oxide gas with ex-vivo lung perfusion compared to lung perfusion alone in human...

15:27
Baker's yeast survive and grow after a drastic reorganization, not of their genes, but of the chromosome superstructures that house, protect and control access to their DNA code, a study just published in Nature finds.  ...

13:33
Lenox Hill Hospital and The Feinstein Institute for Medical Research have been chosen as study site to identify biomarkers for focal seizures in patients with treatment-resistant epilepsy. Researchers hope the study, called Human Epilepsy Project...

10:00
Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery....

09:47
Chemically coated, ceramic implants successfully guided the regrowth of missing bone in lab animals while "steadily dissolving," researchers report.   Surgeons and scientists at NYU School of Medicine and NYU College of...

09:25
RXi Pharmaceuticals Corporation a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, today announced positive results with RXI-109 in a...

09:03
Wills Eye Hospital has been given Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to Retinitis Pigmentosa (RP). The Alpha AMS is...

08:30
OWC Pharmaceutical Research Corp. , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study...

07:30
Imprimis Pharmaceuticals, Inc. through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis's...

07:16
Cantargia AB announce that the Chinese patent authority, State Intellectual Property Office ("SIPO") has issued a formal approval concerning the company's patent application of the immuno-oncological antibody CAN04 (nidanilimab). CAN04 binds...

07:00
ITUS Corporation today announced that it and its research partner, Moffitt Cancer Center, have requested a meeting with the US FDA to review the plan for advancing their CAR-T therapy for Ovarian Cancer into human clinical trials.  ...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18